The Northland Securities Reaffirms “Buy” Rating for Viewray Inc (VRAY)

The Northland Securities Reaffirms “Buy” Rating for Viewray Inc (VRAY)

“We are maintaining our FY17 & FY18 numbers, and our PT & ratings remain the same. Key Points Perhaps the most interesting takeaway from the call was the announcement of a multi-institutional trial on unresectable pancreatic cancer using MRIdian. It is our understanding that this trial will include both MRIdian Cobalt & LINAC (as they become available); will include a hard endpoint like survival, and possibly” intraop dose titration and impact on outcomes. As a reminder, most patients with pancreatic cancer will die within 1 – 2 years, with median survival @ 1-year. Hence, it is certainly possible that ViewRay could provide survival endpoints for such a trial in late 2018 / early 2019. This obviously is predicated on the trial design, sample size, inclusion criteria, and whether this will be randomized or not. The ideal design would obviously be to include a comparative arm with another RT machine (like the TruBeam) & compare to MRIdian. Finally, how outcomes will be influenced with the use of Cobalt vs. LINAC will also be interesting to note, although it might be hard to draw any statistical conclusions given small sample size.”,” the firm’s analyst wrote.

Northland Securities reiterated their buy rating on shares of Viewray Inc (NASDAQ:VRAY) in a research report sent to investors on Tuesday, May 16th. Northland Securities currently has a $7.00 price objective on the stock.

A number of other research firms also recently commented on VRAY. ValuEngine downgraded Viewray from a hold rating to a sell rating in a research note on Thursday, May 11th. Aegis reaffirmed a buy rating and issued a $11.00 price target on shares of Viewray in a research note on Tuesday, May 16th. Shares of Viewray (VRAY) opened at 6.69 on Tuesday. The company’s 50-day moving average is $6.57 and its 200 day moving average is $5.38. The stock’s market cap is $383.89 million. Viewray has a 1-year low of $2.64 and a 1-year high of $10.39.

In other Viewray news, insider Fmr Llc sold 101,139 shares of the business’s stock in a transaction dated Monday, April 24th. The stock was sold at an average price of $6.71, for a total transaction of $678,642.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders have sold 1,385,274 shares of company stock valued at $10,463,829. Insiders own 59.10% of the company’s stock. Hedge funds have recently made changes to their positions in the stock. Sequoia Financial Advisors LLC boosted its stake in shares of Viewray by 25.0% in the first quarter. Sequoia Financial Advisors LLC now owns 25,000 shares of the company’s stock valued at $213,000 after buying an additional 5,000 shares during the last quarter. UBS Group AG boosted its stake in shares of Viewray by 447.7% in the first quarter. UBS Group AG now owns 22,479 shares of the company’s stock valued at $192,000 after buying an additional 18,375 shares during the last quarter. Highbridge Capital Management LLC bought a new stake in shares of Viewray during the first quarter valued at approximately $167,000. Boston Financial Mangement LLC bought a new stake in shares of Viewray during the first quarter valued at approximately $170,000. Finally, HighTower Advisors LLC bought a new stake in shares of Viewray during the first quarter valued at approximately $170,000. Institutional investors and hedge funds own 58.98% of the company’s stock.

Viewray Company Profile ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:VRAY”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Viewray Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Viewray Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment